Markel Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Markel Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-30,500	Closed	-$22M	–	135
2022 Q4	$22M	Sell	30,500 -49,800	-62%	-$36.7M	0.3%	71
2022 Q3	$55.3M	Hold	80,300	–	–	0.82%	34
2022 Q2	$47.5M	Hold	80,300	–	–	0.68%	39
2022 Q1	$56.1M	Buy	80,300 +1,000	+1%	+$633K	0.67%	39
2021 Q4	$50.1M	Buy	79,300 +5,000	+7%	+$3.07M	0.57%	50
2021 Q3	$45M	Buy	74,300 +7,500	+11%	+$4.66M	0.57%	50
2021 Q2	$37.3M	Buy	66,800 +21,300	+47%	+$10.8M	0.47%	56
2021 Q1	$21.5M	Buy	+45,500	New	+$22.2M	0.3%	74

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Markel Group's REGN Position: Q1 2023 in Review

Markel Group sold out of Regeneron Pharmaceuticals (REGN) in Q1 2023, closing a stake of 30,500 shares — an estimated $22M sold.

Markel Group first reported a position in REGN in Q1 2021 and held it in 8 quarters. The position peaked at $56.1M in Q1 2022. 1,191 funds tracked by Wall St. Rank hold REGN as of Q1 2023.

Markel Group reported no remaining Regeneron Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Markel Group sold 30,500 Regeneron Pharmaceuticals shares in Q1 2023, an estimated $22M.
Markel Group first reported a position in Regeneron Pharmaceuticals in Q1 2021 and held it in 8 quarters.
Markel Group's Regeneron Pharmaceuticals position peaked at $56.1M in Q1 2022.
1,191 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.

Based on Markel Group's 13F filing for Q1 2023, filed 28 Apr 2023.